Showing posts with label GOG 0126-T. Show all posts
Showing posts with label GOG 0126-T. Show all posts
Monday, March 14, 2011
PharmaLive: Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer (negative study ovarian/Belinostat/Carboplatin)
Ovarian cancer – GOG 0126-T (NCI-driven study)
Preliminary analysis of GOG 0126-T trial has not shown enough activity to enter into second stage. Consequently the study will be ended.
The study
The study is an open-label single-arm phase II trial with belinostat in combination with carboplatin given to patients with ovarian cancer who progress during or shortly after first-line treatment with platinum containing chemotherapy. The trial is sponsored by the GOG with support from the NCI. Belinostat is administered as a 30-minute daily IV infusion on day one through five with carboplatin being administered on day three. Treatment is given every third week and is repeated until disease progression......
add your opinions
belinostat
,
Carboplatin
,
clinical trial
,
GOG 0126-T
,
NCI
,
negative study
Subscribe to:
Posts
(
Atom
)